Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways

被引:5
|
作者
Liang, Lusha W. [1 ]
Hasegawa, Kohei [4 ]
Maurer, Mathew S. [1 ]
Reilly, Muredach P. [1 ,2 ]
Fifer, Michael A. [3 ]
Shimada, Yuichi J. [1 ,3 ]
机构
[1] Columbia Univ, Dept Med, Div Cardiol, Irving Med Ctr, 622 W 168th St,PH 3-342, New York, NY 10032 USA
[2] Columbia Univ, Irving Med Ctr, Irving Inst Clin & Translat Res, New York, NY USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA
关键词
cardiomyopathy; hypertrophic; gene expression profiling; inflammation; microRNAs; mutation; DIASTOLIC DYSFUNCTION; CARDIAC-HYPERTROPHY; ENRICHMENT ANALYSIS; MANAGEMENT; EXPRESSION; FIBROSIS; DISEASE;
D O I
10.1161/CIRCHEARTFAILURE.122.010010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Hypertrophic cardiomyopathy (HCM) is caused by mutations in genes coding for proteins essential for myocardial contraction. However, it remains unclear through which signaling pathways these gene mutations mediate HCM pathogenesis. Growing evidence indicates that microRNAs (miRNAs) play an important role in the regulation of gene expression. We hypothesized that transcriptomics profiling of plasma miRNAs would reveal circulating biomarkers and dysregulated signaling pathways in HCM. Methods:We conducted a multicenter case-control study of cases with HCM and controls with hypertensive left ventricular hypertrophy. We performed plasma transcriptomics profiling of miRNAs using RNA sequencing. We developed a transcriptomics-based discrimination model using samples retrieved during the first two-thirds of the study period at one institution (training set). We prospectively tested its discriminative ability in samples collected thereafter from the same institution (prospective test set). We also externally validated the model by applying it to samples collected from the other institutions (external test set). We executed pathway analysis of dysregulated miRNAs with univariable PResults:This study included 555 patients (392 cases and 163 controls). One thousand one hundred forty-one miRNAs passed our quality control filters. The area under the receiver operating characteristic curve of the transcriptomics-based model derived from the training set was 0.86 (95% CI, 0.79-0.93) in the prospective test set and 0.94 (95% CI, 0.90-0.97) in the external test set. Pathway analysis revealed dysregulation of the Ras-MAPK (mitogen-activated protein kinase) pathway and pathways related to inflammation in HCM. Conclusions:This study utilized comprehensive transcriptomics profiling with RNA sequencing in HCM, revealing circulating miRNA biomarkers and dysregulated pathways.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Comprehensive Sequencing of Small Non-Coding RNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways
    Shimada, Yuichi J.
    Hasegawa, Kohei
    Fifer, Michael A.
    CIRCULATION, 2021, 144
  • [2] Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy
    Lumish, Heidi S.
    Sherrid, Mark V.
    Janssen, Paul M. L.
    Ferrari, Giovanni
    Hasegawa, Kohei
    Castillero, Estibaliz
    Adlestein, Elizabeth
    Swistel, Daniel G.
    Topkara, Veli K.
    Maurer, Mathew S.
    Reilly, Muredach P.
    Shimada, Yuichi J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (20) : 1999 - 2011
  • [3] Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy
    Shimada, Yuichi J.
    Raita, Yoshihiko
    Liang, Lusha W.
    Maurer, Mathew S.
    Hasegawa, Kohei
    Fifer, Michael A.
    Reilly, Muredach P.
    CIRCULATION-HEART FAILURE, 2021, 14 (07) : 777 - 787
  • [4] Comprehensive Proteomics Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Severe Forms of Hypertrophic Cardiomyopathy
    Hartman, Heidi
    Sherrid, Mark
    Hasegawa, Kohei
    Adlestein, Elizabeth
    Swistel, Daniel
    Tower-Rader, Albree
    Fifer, Michael A.
    Topkara, Veli K.
    Maurer, Mathew S.
    Reilly, Muredach P.
    Shimada, Yuichi
    CIRCULATION, 2023, 148
  • [5] Comprehensive Proteomics Profiling of Myocardium Identifies Dysregulated Signaling Pathways in Hypertrophic Cardiomyopathy
    Lumish, Heidi S.
    Liang, Lusha
    Hasegawa, Kohei
    Adlestein, Elizabeth
    Swistel, Daniel
    Maurer, Mathew S.
    Reilly, Muredach P.
    Sherrid, Mark
    Shimada, Yuichi J.
    CIRCULATION, 2022, 146
  • [6] Comprehensive Plasma Proteomics Profiling Identifies Signaling Pathways Dysregulated in Genotype-Positive versus GenotypeNegative Patients With Hypertrophic Cardiomyopathy
    Akita, Keitaro
    Hasegawa, Kohei
    Maurer, Mathew S.
    Rader, Albree Tower
    Fifer, Michael A.
    Topkara, Veli K.
    Reilly, Muredach P.
    Shimada, Yuichi
    CIRCULATION, 2023, 148
  • [7] Letter by Luo and Bu Regarding Article, "Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy"
    Luo, Fanyany
    Bu, Haisong
    CIRCULATION-HEART FAILURE, 2022, 15 (06)
  • [8] Response by Liang and Shimada to Letter Regarding Article "Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy"
    Liang, Lusha W.
    Shimada, Yuichi J.
    CIRCULATION-HEART FAILURE, 2022, 15 (06)
  • [9] Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy
    Hao Cui
    Yifan Wang
    Xiumeng Hua
    Jing Han
    Han Mo
    Shun Liu
    Hongmei Wang
    Siyuan Huang
    Yiqi Zhao
    Xiao Chen
    Qian Zhao
    Hao Jia
    Yuan Chang
    Jiangping Song
    Biomarker Research, 13 (1)
  • [10] Comprehensive Plasma Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy from Other Cardiomyopathies with Left Ventricular Hypertrophy
    Akita, Keitaro
    Maurer, Mathew
    Rader, Albree Tower
    Fifer, Michael
    Reilly, Muredach
    Shimada, Yuichi
    CIRCULATION, 2024, 150